Yunsong Yu Selected Research

Tigecycline (Tygacil)

9/2022	Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
5/2022	Evaluation of the in vitro synergy of polymyxin B-based combinations against polymyxin B -resistant gram-negative bacilli.
1/2022	Risk factors for infection and mortality caused by carbapenem-resistant Klebsiella pneumoniae: A large multicentre case-control and cohort study.
12/2021	Resistance evolution of hypervirulent carbapenem-resistant Klebsiella pneumoniae ST11 during treatment with tigecycline and polymyxin.
12/2021	Novel tigecycline resistance mechanisms in Acinetobacter baumannii mediated by mutations in adeS, rpoB and rrf.
12/2018	Tigecycline resistance caused by rpsJ evolution in a 59-year-old male patient infected with KPC-producing Klebsiella pneumoniae during tigecycline treatment.
1/2018	The Rapid Emergence of Tigecycline Resistance in blaKPC-2 Harboring Klebsiella pneumoniae, as Mediated in Vivo by Mutation in tetA During Tigecycline Treatment.
1/2018	Emergence of tigecycline resistance in Escherichia coli co-producing MCR-1 and NDM-5 during tigecycline salvage treatment.
4/2016	Rapid emergence of high-level tigecycline resistance in Escherichia coli strains harbouring blaNDM-5 in vivo.
1/2016	Step-Wise Increase in Tigecycline Resistance in Klebsiella pneumoniae Associated with Mutations in ramR, lon and rpsJ.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yunsong Yu Research Topics

Disease

51	Infections 12/2022 - 08/2003
7	Intraabdominal Infections 09/2022 - 06/2010
5	Sepsis (Septicemia) 01/2022 - 12/2014
5	Cross Infection (Nosocomial Infection) 01/2022 - 01/2015
4	Pneumonia (Pneumonitis) 09/2020 - 03/2009
3	Urinary Tract Infections (Urinary Tract Infection) 09/2022 - 09/2018
3	Neoplasms (Cancer) 12/2021 - 05/2020
3	Respiratory Tract Infections (Respiratory Tract Infection) 12/2020 - 11/2011
3	Bacteremia 09/2020 - 03/2019
3	Soft Tissue Infections 11/2018 - 10/2016
2	Gram-Negative Bacterial Infections 09/2022 - 01/2018
2	Communicable Diseases (Infectious Diseases) 04/2022 - 01/2021
2	Bacterial Infections (Bacterial Infection) 12/2021 - 01/2016
2	Ascites 01/2021 - 01/2018
2	Chronic Hepatitis B 01/2019 - 01/2017
2	Pulmonary Aspergillosis 11/2018 - 04/2018
1	Pneumococcal Infections 12/2022
1	Ventilator-Associated Pneumonia 09/2022
1	Hematologic Neoplasms (Hematological Malignancy) 01/2022
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022
1	Respiratory Sounds (Crackle) 01/2022
1	Cholangitis 12/2021
1	Inflammation (Inflammations) 11/2021
1	COVID-19 11/2021
1	Multiple Organ Failure (MODS) 11/2021
1	Wounds and Injuries (Trauma) 11/2021
1	Disease Progression 11/2021
1	Neutropenia 02/2021
1	Urinary Calculi (Urinary Calculus) 01/2021
1	Jaundice (Icterus) 01/2021
1	Liver Failure 01/2021
1	Enterobacteriaceae Infections 12/2020
1	Fistula 12/2020
1	Intracranial Hypertension 10/2020
1	Cryptococcal Meningitis 10/2020
1	Escherichia coli Infections 05/2020
1	Suppuration 05/2020
1	Hemolysis 01/2020
1	Endocarditis 01/2020
1	Critical Illness (Critically Ill) 01/2020
1	Persistent Infection 01/2020
1	Splenomegaly 01/2019

Drug/Important Bio-Agent (IBA)

22	Anti-Bacterial Agents (Antibiotics)IBA 09/2022 - 03/2009
19	Carbapenems (Carbapenem Antibiotics)IBA 09/2022 - 01/2017
15	Tigecycline (Tygacil)FDA Link 09/2022 - 07/2010
8	Pharmaceutical PreparationsIBA 12/2021 - 08/2013
5	Fosfomycin FDA Link 12/2022 - 08/2014
5	Anti-Infective Agents (Microbicides)IBA 01/2021 - 08/2003
4	LactamsIBA 09/2022 - 01/2021
4	ceftazidime drug combination avibactamIBA 09/2022 - 11/2018
4	Colistin (Coly-Mycin)FDA Link 05/2022 - 01/2017
3	Cephalosporins (Cephalosporin Antibiotics)IBA 09/2022 - 01/2017
3	VaccinesIBA 01/2022 - 09/2020
3	carbapenemaseIBA 12/2021 - 01/2021
3	Amikacin (A.M.K)FDA LinkGeneric 01/2018 - 03/2016
2	Conjugate VaccinesIBA 12/2022 - 01/2022
2	CefiderocolIBA 09/2022 - 01/2022
2	AminoglycosidesIBA 09/2022 - 01/2022
2	avibactamIBA 05/2022 - 11/2018
2	Polymyxins (Polymyxin)IBA 12/2021 - 04/2017
2	Imipenem FDA Link 12/2020 - 01/2017
2	Linezolid (Zyvox)FDA Link 01/2020 - 10/2016
2	Antiviral Agents (Antivirals)IBA 01/2019 - 01/2017
2	Immunoglobulin M (IgM)IBA 11/2018 - 12/2017
1	FluoroquinolonesIBA 09/2022
1	eravacyclineIBA 09/2022
1	CytokinesIBA 01/2022
1	beta Lactam AntibioticsIBA 01/2022
1	beta-LactamsIBA 01/2022
1	QuinolonesIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 12/2021
1	fibrin fragment D (D-dimer)IBA 11/2021
1	BilirubinIBA 01/2021
1	NanoconjugatesIBA 01/2021
1	Clavulanic Acid (Potassium Clavulanate)FDA LinkGeneric 01/2021
1	Penicillins (Penicillin)FDA Link 01/2021
1	Ceftriaxone (Ceftriaxon)FDA LinkGeneric 01/2021
1	relebactamIBA 12/2020
1	Amphotericin B (Amphotericin)FDA LinkGeneric 10/2020
1	Moxifloxacin (Avelox)FDA Link 10/2020
1	Glycoproteins (Glycoprotein)IBA 09/2020
1	GlycoconjugatesIBA 09/2020
1	CreatinineIBA 01/2020
1	Capsules (Microcapsules)IBA 01/2020
1	Urea (Carbamide)FDA LinkGeneric 01/2020
1	Daptomycin FDA Link 01/2020
1	Virulence Factors (Pathogenicity Factors)IBA 01/2020
1	Alanine Transaminase (SGPT)IBA 01/2019
1	DNA (Deoxyribonucleic Acid)IBA 01/2019
1	Levofloxacin (Levaquin)FDA Link 11/2018
1	Ciprofloxacin (Cipro)FDA LinkGeneric 11/2018
1	Ceftaroline FDA Link 11/2018

Therapy/Procedure

15	Therapeutics 12/2022 - 03/2009
2	Critical Care (Surgical Intensive Care) 04/2022 - 12/2020
1	Tracheotomy 01/2022
1	Endovascular Procedures 01/2022
1	Catheters 01/2022
1	Lithotripsy (Extracorporeal Shockwave Lithotripsy) 01/2021
1	Intraperitoneal Injections 09/2020
1	Central Venous Catheters 05/2020